• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of new or reformulated infant formula notification reviews completed during the month within 90 days of filing

Dictionary: Timely review of notifications for new and reformulated infant formulas is essential for protecting the health and well being of infants. Since these statutory requirements are notifications rather than pre-market approvals, it is essential that ONLDS have completed review of the information before the submitter markets the product, to notify them of any safety or regulatory concerns before the product reaches consumers.

Information is current as of March 31, 2014.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeAnnual TargetPercentage
Oct 20099050
Nov 20099075
Dec 20099088
Jan 201090100
Feb 201090100
Mar 20109050
Apr 201090N/A
May 201090100
Jun 201090100
Jul 201090100
Aug 201090100
Sep 201090100

FY 2010 Overall: 86%

Number of infant formula notification reviews completed during the month within 90 days of filing

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2009N/A1
Nov 2009N/A3
Dec 2009N/A7
Jan 2010N/A5
Feb 2010N/A1
Mar 2010N/A2
Apr 2010N/A0
May 2010N/A6
Jun 2010N/A3
Jul 2010N/A1
Aug 2010N/A2
Sep 2010N/A1

FY 2010 Total: 32

Total number of infant formula notification reviews completed during the month

Fiscal Year - 2010
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2009N/A2
Nov 2009N/A4
Dec 2009N/A8
Jan 2010N/A5
Feb 2010N/A1
Mar 2010N/A4
Apr 2010N/A0
May 2010N/A6
Jun 2010N/A3
Jul 2010N/A1
Aug 2010N/A2
Sep 2010N/A1

FY 2010 Total: 37

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.